You just read:

AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis

News provided by

AbbVie

Sep 11, 2017, 08:01 ET